Randomized Phase II Trial of Chemotherapy of Physician's Choice Plus Trastuzumab Versus Chemotherapy of Physician's Choice Plus Trastuzumab Plus Pertuzumab In Women With Pretreated, HER2-Overexpressing Metastatic Breast Cancer (MBC)

Trial Profile

Randomized Phase II Trial of Chemotherapy of Physician's Choice Plus Trastuzumab Versus Chemotherapy of Physician's Choice Plus Trastuzumab Plus Pertuzumab In Women With Pretreated, HER2-Overexpressing Metastatic Breast Cancer (MBC)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 23 May 2017

At a glance

  • Drugs Pertuzumab (Primary) ; Capecitabine; Docetaxel; Paclitaxel; Trastuzumab; Vinorelbine
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Sponsors US Oncology Research
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 18 May 2017 Status changed from recruiting to active, no longer recruiting.
    • 14 Jan 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top